retatrutide clinical trial doses ESC 2024: improves lipid and cardiovascular risk profile in Phase II retatrutide clinical trial dosing frequency

Who should look elsewhere: Anyone needing significant weight loss

Safety watch remains important The current obesity trial reported dysesthesia in 12.5% of patients on the 12 mg dose, lower than the 20.9% seen in a previous trial

There is no end date for eligibility to submit a data-sharing request for these data

Weight loss is subtleseveral pounds over eight weeksbut steadier moods and fewer binges matter

Bananas get the publicity, but potatoes, avocados, and leafy greens actually contain more potassium per serving

Every stage from the conclusion of clinical trials to worldwide dissemination presents its own complexities